跳至主要内容
临床试验/2022-501477-40-00
2022-501477-40-00招募中1 期

A study to learn the effects of ripretinib (study drug) on how midazolam behaves in the body of people with advanced gastrointestinal stromal tumor

Deciphera Pharmaceuticals Inc.6 个研究点 分布在 3 个国家目标入组 22 人开始时间: 2023年8月28日最近更新:

试验速览

阶段
1 期
状态
招募中
入组人数
22
试验地点
6

研究概览

简要总结

暂无简介。

入排标准

年龄范围
18 years 至 65+ years(65+ Years, 18-64 Years)
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Pharmaceutical company
责任方
Principal Investigator
主要研究者

Clinical trial information

Scientific

Deciphera Pharmaceuticals Inc.

研究点 (6)

Loading locations...

相似试验

招募中
1 期
A study to learn the effects of ripretinib (study drug) on how midazolam behaves in the body of people with advanced gastrointestinal stromal tumorAdvanced Gastrointestinal Stromal TumorMedDRA version: 21.1Level: PTClassification code: 10051066Term: Gastrointestinal stromal tumour Class: 100000004864
CTIS2022-501477-40-00Deciphera Pharmaceuticals Inc.22
招募中
3 期
52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in comparison to placebo with omalizumab as active control in adult patients with CSU and inadequate response to H1-antihistamine and an open-label 52-week optional extension to assess long-term efficacy, safety and tolerability of remibrutinib 25 mg b.i.d.
2022-502161-19-00Novartis Pharma AG214
已完成
2 期
A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions
2023-510306-40-00Janssen Cilag International6
招募中
3 期
A Study of LY3437943 in Participants with Type 2 Diabetes Mellitus who have Obesity or Overweight (TRIUMPH-2)ObesityType 2 Diabetes
2023-503658-11-00Eli Lilly & Co.235
招募中
3 期
Comparison between rituximab plus zanubrutinib versus rituximab monotherapy in untreated splenic marginal zone lymphoma patients
2023-503755-10-00Association International Extranodal Lymphoma Study Group90